Nuvo Pharmaceuticals (OTCMKTS:MRVFF) and Vectura Group (OTCMKTS:VEGPF) Head-To-Head Survey

Profitability

This table compares Vectura Group and Nuvo Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vectura Group	N/A	N/A	N/A
Nuvo Pharmaceuticals	20.88%	-1,996.22%	14.25%

Risk and Volatility

Vectura Group has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Comparatively, Nuvo Pharmaceuticals has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.

Valuation & Earnings

This table compares Vectura Group and Nuvo Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vectura Group	$244.76 million	4.37	$157.16 million	$0.26	6.81
Nuvo Pharmaceuticals	$54.98 million	0.20	-$25.70 million	($0.12)	-8.16

Vectura Group has higher revenue and earnings than Nuvo Pharmaceuticals. Nuvo Pharmaceuticals is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

Summary

Vectura Group beats Nuvo Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

About Vectura Group

Vectura Group Plc engages in the provision of pharmaceutical development. Its activities include research, development, and commercialization of novel therapeutic products. The company operates through the following segments: Switzerland, United Kingdom, Germany, United States of America, and France. Vectura Group was founded by David Anthony Gough in 1997 and is headquartered in Chippenham, the United Kingdom.

About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.